Alpha Biopharma Inc.

Hong Kong-listed TYK Medicines has claimed TY-9591, its third-generation EGFR inhibitor, outperformed AstraZeneca’s same-class blockbuster Tagrisso (osimertinib) in the first-line treatment of brain m

Wugen Inc. has raised nearly $200m to date to fund its natural killer (NK) cell and chimeric antigen receptor T-cell (CAR-T) therapies, including a $172m series B venture capital round announced on 1

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Otsuka Picks Up Perception’s R-Ketamine